Skip to main contentSkip to navigationSkip to search
SEK  %

Interim report Q1/2023: Strong start to the year – Enzymatica’s growth journey continues according to plan

Regulatory information

First quarter

  • Net sales reached SEK 13.0 (4.2) million.
  • The operating result totaled SEK -14.4 (-18.1) million.
  • Earnings per share, basic and diluted, were SEK -0.09 (-0.12).
  • Cash flow from operating activities totaled SEK -12.2 (-10.2) million. Cash flow was impacted by payment of one-off compensation to partners totaling SEK 5.6 million.


Significant events during the quarter

Significant events after the quarter


  • No significant events were reported
    during the quarter.


  • No significant events were reported
    after the end of the quarter.


Other events during the quarter



  • Enzymatica’s mouth spray will be launched in Jordan in April by MS Pharma, under the ViruProtect brand.



”Sales in the first quarter of the year increased by over 200% compared with the same period last year. The
comparison is against a weak quarter in 2022, but it is reassuring to see that Enzymatica is back on the growth journey that took an unexpected and challenging break during the pandemic. A clear increase in demand can be seen both in Sweden and our partner markets. Sales in the first quarter were in line with the same period in 2019, which was the last year when sales were not affected by the pandemic”, said Claus Egstrand, CEO of Enzymatica.


The full year-end report is available on:


This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET on April 27, 2023.


For more information, please contact:

Claus Egstrand, Chief Executive Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email:

Stefan Olsson, Communication Manager, Enzymatica AB
Phone: +46 708 55 11 85 | Email:


Enzymatica AB is headquartered in Lund, Sweden, and is listed on Nasdaq First North Growth Market.
For more information, please visit Enzymatica’s Certified Adviser is Erik Penser Bank.